scripod.com
Novo Nordisk (Ozempic)

Overview

Shownote

Highlights

Transcript

Chapters

Pins

Novo Nordisk (Ozempic)

Acquired

2024/01/22
Acquired

Acquired

2024/01/22
OverviewShownoteHighlightsTranscriptChaptersPins

Shownote

Last year Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, overtook LVMH to become Europe’s most valuable company. And the pull for Acquired to finally tackle healthcare (18% of US GDP!) became too strong for us to resist. While w...

Highlights

Few companies embody transformation quite like Novo Nordisk—a century-old pharmaceutical pioneer that didn’t just adapt to change but engineered its own revolution. From life-saving insulin to the blockbuster drugs reshaping how we treat obesity, this is a story of scientific persistence, strategic foresight, and a mission-driven culture that defied industry norms.
06:03
Insulin transformed type 1 diabetes from a death sentence to a manageable condition
31:02
The foundation structure enabled long-term R&D investment and public health access.
49:08
Novo won the Danish Supreme Court case against Nordisk over insulin patents.
1:23:03
PBMs act as gatekeepers determining patient access to medications through formulary control.
1:36:01
The rejection of the Serono merger allowed Novo Nordisk to retain control of its groundbreaking GLP-1 research.
2:09:45
Semaglutide shows greater efficacy and longer-lasting effects than liraglutide
2:18:12
Novo Nordisk's market cap grew from $100B in 2020 to nearly $500B in 2023 due to GLP-1 demand
2:20:56
Semaglutide could be a miracle drug for humanity and a financial boon for Novo Nordisk.
2:40:44
Novo Nordisk created the GLP-1 market unintentionally and now dominates it.
2:57:48
Novo Holdings is the world's largest life sciences endowment with $120 billion.
3:00:42
Novo Nordisk's executives are not incentivized by stock price, and employees may have lower compensation.
3:09:09
Only 10% of drugs in clinical development reach the market, and one drug can provide half the profits.
3:11:59
Most approved drugs don't recoup their R&D costs
3:30:48
GLP-1 drugs could be the next super-cycle with high barriers to entry and broad demand.

Chapters

How a diabetic wife sparked a medical empire
00:00
The nonprofit that built a pharma giant
31:02
When insulin became a battlefield
40:17
Why biotech left one rival behind
1:11:06
The merger that almost derailed a revolution
1:32:35
The woman who refused to give up on a failing hormone
1:39:44
From diabetes drug to weight-loss phenomenon
2:12:39
How a miracle molecule exposed broken incentives
2:20:56
Why millions still can’t access the treatment they need
2:35:00
The patent machine powering generational profits
2:43:20
A company that doesn’t answer to Wall Street
3:00:42
Why pharma stopped chasing cures for everyone
3:06:15
The crushing cost of inventing new drugs
3:11:59
Can medicine survive its own success?
3:17:12
What comes after Ozempic?
3:33:28

Transcript

David Rosenthal: All right, first episode back. Let's see if I can do this sleep-deprived. Ben Gilbert: Oh, you and me both, man. Who got the truth? Is it you? Is it you? Is it you? Who got the truth now? Is it you? Is it you? Is it you? Sit me down, say ...